MiR-873/PD-L1 axis regulates the stemness of breast cancer cells

被引:119
|
作者
Gao, Lanlan [1 ,2 ]
Guo, Qianqian [1 ,2 ]
Li, Xiaoman [3 ]
Yang, Xuan [1 ,2 ]
Ni, Haiwei [1 ,2 ]
Wang, Ting [1 ,2 ]
Zhao, Qiong [1 ,2 ]
Liu, Hai [1 ,2 ]
Xing, Yingying [1 ,2 ]
Xi, Tao [1 ,2 ]
Zheng, Lufeng [1 ,2 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China
[3] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing 210023, Jiangsu, Peoples R China
来源
EBIOMEDICINE | 2019年 / 41卷
基金
中国博士后科学基金;
关键词
miR-873; PD-L1; Cancer stem cells; Drug resistance; PI3K/Akt; ERK1/2; PD-L1; EXPRESSION; TUMOR-SUPPRESSOR; IFN-GAMMA; TAMOXIFEN RESISTANCE; DRUG-RESISTANCE; TARGETING CDK3; B7-H1; METASTASIS; CHEMORESISTANCE; PROGRESSION;
D O I
10.1016/j.ebiom.2019.02.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Breast cancer stem cells have self-renewal capability and are resistant to conventional chemotherapy. PD-L1 could promote the expression of stemness markers (OCT4 and Nanog) in breast cancer stem cells. However, the mechanisms by which PD-L1 regulates the stemness of breast cancer cells and PD-L1 is regulated in breast cancer cells are still unclear. Methods: Lentivirus infectionwas used to construct stable cell lines. The correlation between PD-L1 and stemness markers expression was evaluated in clinical samples. Additionally, luciferase reporter assay combined with RNA-Fluorescence in situ hybridization (RNA-FISH) and RNA-binding protein immunoprecipitation (RIP) assays were used to verify the direct binding of miR-873 on PD-L1. Furthermore, flowcytometry, mammosphere formation combined with nude mouse tumor xenograftmodel were carried out to examine the effects ofmiR-873/PDL1 axis on the stemness of breast cancer cells. Finally, MTT assay was performed to determine the effects of miR873/ PD-L1 axis on drug resistance. Findings: PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K/Akt and ERK1/2 pathways. Mechanistically, miR-873 inhibited PD-L1 expression through directly binding to its 3'-untranslated region (UTR), and miR-873 attenuated the stemness and chemoresistance of breast cancer cells which was dependent on PD-L1 and the downstream PI3K/Akt and ERK1/2 signaling. Notably, the promotion of PD-L1 on the stemness and chemoresistance was enhanced by recombinant PD-1 (rPD-1), this effect was attenuated by PD-1/PD-L1 inhibitor. Interpretation: miR-873/PD-L1 regulatory axis might serve as a therapeutic target to enhance the chemosensitivity and eliminate the stemness of breast cancer cells. Fund: This work was supported by the National Nature Science Foundation of China, No. 81702957, China Postdoctoral Science Foundation, No. 2017M620230, the Postdoctoral Research Funding Scheme of Jiangsu Province (2017), No. 1701197B, and the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions. (c) 2019 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:395 / 407
页数:13
相关论文
共 50 条
  • [41] PD-L1 protein expression in breast cancer
    Saastad, Sigurd A.
    Skjervold, Anette H.
    Ytterhus, Borgny
    Engstrom, Monica Jernberg
    Bofin, Anna M.
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (11) : 730 - 736
  • [42] MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer
    Yang, Meng
    Xiao, Ran
    Wang, Xinru
    Xiong, Youyi
    Duan, Zhenfeng
    Li, Duolu
    Kan, Quancheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
  • [43] The association of lentinan with PD-1/PD-L1 axis in gastric cancer
    Ina, K.
    Kataoka, T.
    Ina, H.
    Yoneda, M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 212 - 212
  • [44] Cancer cell expression of CCR2 regulates the PD-L1/PD-1 immune checkpoint in breast cancer
    Fein, Miriam R.
    Almeida, Ana S.
    Eberhardt, Anais
    Egeblad, Mikala
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [45] Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1
    Wang, Gangyue
    Dong, Yi
    Liu, Heng
    Ji, Nan
    Cao, Jilei
    Liu, Aihui
    Tang, Xin
    Ren, Yu
    ONCOLOGY LETTERS, 2019, 18 (04) : 3837 - 3844
  • [46] HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis
    Linsong Mu
    Yeli Wang
    Hailong Su
    Yang Lin
    Wu Sui
    Xiang Yu
    Zhongchuan Lv
    Digestive Diseases and Sciences, 2021, 66 : 4314 - 4325
  • [47] HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis
    Mu, Linsong
    Wang, Yeli
    Su, Hailong
    Lin, Yang
    Sui, Wu
    Yu, Xiang
    Lv, Zhongchuan
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (12) : 4314 - 4325
  • [48] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [49] Prognostic significance of PD-L1 and PD-L2 in breast cancer
    Baptista, Mauricio Z.
    Sarian, Luis Otavio
    Derchain, Sophie F. M.
    Pinto, Glauce A.
    Vassal, Jose
    HUMAN PATHOLOGY, 2016, 47 (01) : 78 - 84
  • [50] PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer
    Manson, Quirine F.
    ter Hoeve, Natalie D.
    Buerger, Horst
    Moelans, Cathy B.
    van Diest, Paul J.
    TARGETED ONCOLOGY, 2018, 13 (06) : 769 - 777